BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 8174135)

  • 1. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
    Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
    Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions.
    Peverali FA; Orioli D; Tonon L; Ciana P; Bunone G; Negri M; Della-Valle G
    Oncogene; 1996 Jan; 12(2):457-62. PubMed ID: 8570225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
    Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA binding by N- and L-Myc proteins.
    Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
    Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Max and c-Myc/Max DNA-binding activities in cell extracts.
    Littlewood TD; Amati B; Land H; Evan GI
    Oncogene; 1992 Sep; 7(9):1783-92. PubMed ID: 1501888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
    Vervoorts J; Lüscher B
    Biol Chem; 1999 Sep; 380(9):1121-6. PubMed ID: 10543451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N-myc oncoprotein is a transcriptional activator and associates with max and RB1 proteins.
    Wenzel A; Cziepluch C; Schürmann J; Schwab M
    Prog Clin Biol Res; 1994; 385():59-66. PubMed ID: 7972238
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
    Buckle RS; Méchali M
    Oncogene; 1995 Mar; 10(6):1249-55. PubMed ID: 7700652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells.
    Lutz W; Schwab M
    Oncogene; 1997 Jul; 15(3):303-15. PubMed ID: 9233765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of two distinct homologues of Xenopus Max during early development.
    King MW; Blackwood EM; Eisenman RN
    Cell Growth Differ; 1993 Feb; 4(2):85-92. PubMed ID: 8494787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
    Billaud M; Isselbacher KJ; Bernards R
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2739-43. PubMed ID: 8464883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors.
    Berberich S; Hyde-DeRuyscher N; Espenshade P; Cole M
    Oncogene; 1992 Apr; 7(4):775-9. PubMed ID: 1565473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.